Engineering animal models of dystonia
Janneth Oleas BS
Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida
Search for more papers by this authorFumiaki Yokoi PhD
Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida
Search for more papers by this authorMark P. DeAndrade MS
Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida
Search for more papers by this authorAntonio Pisani MD
Department of Neuroscience, University Tor Vergata/Laboratory of Neurophysiology and Synaptic Plasticity, Fondazione Santa Lucia Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
Search for more papers by this authorCorresponding Author
Yuqing Li PhD
Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida
Correspondence to: Dr. Yuqing Li, Department of Neurology, College of Medicine, University of Florida, PO Box 100236, Gainesville, FL 32610; [email protected]Search for more papers by this authorJanneth Oleas BS
Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida
Search for more papers by this authorFumiaki Yokoi PhD
Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida
Search for more papers by this authorMark P. DeAndrade MS
Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida
Search for more papers by this authorAntonio Pisani MD
Department of Neuroscience, University Tor Vergata/Laboratory of Neurophysiology and Synaptic Plasticity, Fondazione Santa Lucia Istituto di Ricovero e Cura a Carattere Scientifico, Rome, Italy
Search for more papers by this authorCorresponding Author
Yuqing Li PhD
Department of Neurology, College of Medicine, University of Florida, Gainesville, Florida
Correspondence to: Dr. Yuqing Li, Department of Neurology, College of Medicine, University of Florida, PO Box 100236, Gainesville, FL 32610; [email protected]Search for more papers by this authorSupported by grants from the Tyler's Hope for a Dystonia Care, Inc., the National Institutes of Health (NS37409, NS47466, NS47692, NS54246, NS57098, NS65273, NS72872, and NS74423), and startup funds from the Departments of Neurology at UAB and UF (Yuqing Li).
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full author roles may be found in the Acknowledgments section online.
ABSTRACT
Dystonia is a neurological disorder characterized by abnormal involuntary movements that are prolonged and often cause twisting and turning. Several genetically modified worms, fruit flies, and rodents have been generated as models of genetic dystonias, in particular DYT1, DYT11, and DYT12 dystonias. Although these models do not show overt dystonic symptoms, the rodent models exhibit motor deficits in specialized behavioral tasks, such as the rotarod and beam-walking tests. For example, in a rodent model of DYT12 dystonia, which is generally stress triggered, motor deficits are observed only after the animal is stressed. Moreover, in a rodent model of DYT1 dystonia, the motor and electrophysiological deficits can be rescued by trihexyphenidyl, a common anticholinergic medication used to treat dystonic symptoms in human patients. Biochemically, the DYT1 and DYT11 animal models also share some similarities to patients, such as a reduction in striatal D2 dopamine receptor and binding activities. In addition, conditional knockout mouse models for DYT1 and DYT11 dystonia demonstrate that loss of the causal dystonia-related proteins in the striatum leads to motor deficits. Interestingly, loss of the DYT1 dystonia causal protein in Purkinje cells shows an improvement in motor performance, suggesting that gene therapy targeting of the cerebellum or intervention in its downstream pathways may be useful. Finally, recent studies using DYT1 dystonia worm and mouse models led to a potential novel therapeutic agent, which is currently undergoing clinical trials. These results indicate that genetic animal models are powerful tools to elucidate the pathophysiology and to further develop new therapeutics for dystonia. © 2013 Movement Disorder Society
References
- 1 Albanese A, Bhatia K, Bressman SB, et al. Phenomenology and classification of dystonia: a consensus update. Mov Disord 2013; 28: 863–873.
- 2 Fahn S, Eldridge R. Definition of dystonia and classification of the dystonic states. Adv Neurol 1976; 14: 1–5.
- 3 Bertram KL, Williams DR. Diagnosis of dystonic syndromes—a new eight-question approach. Nat Rev Neurol 2012; 8: 275–283.
- 4 Niethammer M, Carbon M, Argyelan M, Eidelberg D. Hereditary dystonia as a neurodevelopmental circuit disorder: evidence from neuroimaging. Neurobiol Dis 2011; 42: 202–209.
- 5 Tinazzi M, Rosso T, Fiaschi A. Role of the somatosensory system in primary dystonia. Mov Disord 2003; 18: 605–622.
- 6 Zhuang P, Li Y, Hallett M. Neuronal activity in the basal ganglia and thalamus in patients with dystonia. Clin Neurophysiol 2004; 115: 2542–2557.
- 7 Neychev VK, Fan X, Mitev VI, Hess EJ, Jinnah HA. The basal ganglia and cerebellum interact in the expression of dystonic movement. Brain 2008; 131(pt 9): 2499–2509.
- 8 Breakefield XO, Blood AJ, Li Y, Hallett M, Hanson PI, Standaert DG. The pathophysiological basis of dystonias. Nat Rev Neurosci 2008; 9: 222–234.
- 9 Quartarone A, Pisani A. Abnormal plasticity in dystonia: disruption of synaptic homeostasis. Neurobiol Dis 2011; 42: 162–170.
- 10Sadnicka A, Hoffland BS, Bhatia KP, van de Warrenburg BP, Edwards MJ. The cerebellum in dystonia—help or hindrance? Clin Neurophysiol 2012; 123: 65–70.
- 11 Calderon DP, Fremont R, Kraenzlin F, Khodakhah K. The neural substrates of rapid-onset dystonia-parkinsonism. Nat Neurosci 2011; 14: 357–365.
- 12 Ikeda K, Satake S, Onaka T, et al. Enhanced inhibitory neurotransmission in the cerebellar cortex of the Atp1a3-deficient heterozygous mice. J Physiol 2013.
- 13 Raike RS, Jinnah HA, Hess EJ. Animal models of generalized dystonia. NeuroRx 2005; 2: 504–512.
- 14 Ozelius LJ, Hewett JW, Page CE, et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat Genet 1997; 17: 40–48.
- 15 Bressman SB, de Leon D, Brin MF, et al. Idiopathic dystonia among Ashkenazi Jews: evidence for autosomal dominant inheritance. Ann Neurol 1989; 26: 612–620.
- 16 Fahn S. The genetics of idiopathic torsion dystonia. Int J Neurol 1991; 25-26: 70–80.
- 17 Muller U. The monogenic primary dystonias. Brain 2009; 132(pt 8): 2005–2025.
- 18 Ozelius LJ, Hewett JW, Page CE, et al. The gene (DYT1) for early-onset torsion dystonia encodes a novel protein related to the Clp protease/heat shock family. Adv Neurol 1998; 78: 93–105.
- 19Burdette AJ, Churchill PF, Caldwell GA, Caldwell KA. The early-onset torsion dystonia-associated protein, torsinA, displays molecular chaperone activity in vitro. Cell Stress Chaperones 2010; 15: 605–617.
- 20Granata A, Watson R, Collinson LM, Schiavo G, Warner TT. The dystonia-associated protein torsinA modulates synaptic vesicle recycling. J Biol Chem 2008; 283: 7568–7579.
- 21 Bargmann CI. Neurobiology of the Caenorhabditis elegans genome. Science 1998; 282: 2028–2033.
- 22 Shulman JM, Shulman LM, Weiner WJ, Feany MB. From fruit fly to bedside: translating lessons from Drosophila models of neurodegenerative disease. Curr Opin Neurol 2003; 16: 443–449.
- 23 Bilen J, Bonini NM. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 2005; 39: 153–171.
- 24 Consortium CeS. Genome sequence of the nematode C. elegans: a platform for investigating biology. Science 1998; 282: 2012–2018.
- 25 Basham SE, Rose LS. The Caenorhabditis elegans polarity gene ooc-5 encodes a Torsin-related protein of the AAA ATPase superfamily. Development 2001; 128: 4645–4656.
- 26 Caldwell GA, Cao S, Sexton EG, Gelwix CC, Bevel JP, Caldwell KA. Suppression of polyglutamine-induced protein aggregation in Caenorhabditis elegans by torsin proteins. Hum Mol Genet 2003; 12: 307–319.
- 27 Cao S, Gelwix CC, Caldwell KA, Caldwell GA. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J Neurosci 2005; 25: 3801–3812.
- 28 Chen P, Burdette AJ, Porter JC, et al. The early-onset torsion dystonia-associated protein, torsinA, is a homeostatic regulator of endoplasmic reticulum stress response. Hum Mol Genet 2010; 19: 3502–3515.
- 29 Koh YH, Rehfeld K, Ganetzky B. A Drosophila model of early onset torsion dystonia suggests impairment in TGF-beta signaling. Hum Mol Genet 2004; 13: 2019–2030.
- 30 Leung JC, Klein C, Friedman J, et al. Novel mutation in the TOR1A (DYT1) gene in atypical early onset dystonia and polymorphisms in dystonia and early onset parkinsonism. Neurogenetics 2001; 3: 133–143.
- 31 Lee DW, Seo JB, Ganetzky B, Koh YH. DeltaFY mutation in human torsin A [corrected] induces locomotor disability and aberrant synaptic structures in Drosophila. Mol Cells 2009; 27: 89–97.
- 32 Ozelius LJ, Page CE, Klein C, et al. The TOR1A (DYT1) gene family and its role in early onset torsion dystonia. Genomics 1999; 62: 377–384.
- 33 Muraro NI, Moffat KG. Down-regulation of torp4a, encoding the Drosophila homologue of torsinA, results in increased neuronal degeneration. J Neurobiol 2006; 66: 1338–1353.
- 34 Wakabayashi-Ito N, Doherty OM, Moriyama H, et al. Dtorsin, the Drosophila ortholog of the early-onset dystonia TOR1A (DYT1), plays a novel role in dopamine metabolism [serial online]. PLoS One 2011; 6: e26183.
- 35 Dang MT, Yokoi F, McNaught KS, et al. Generation and characterization of Dyt1 DeltaGAG knock-in mouse as a model for early-onset dystonia. Exp Neurol 2005; 196: 452–463.
- 36 Goodchild RE, Kim CE, Dauer WT. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. Neuron 2005; 48: 923–932.
- 37 Yokoi F, Dang MT, Miller CA, et al. Increased c-fos expression in the central nucleus of the amygdala and enhancement of cued fear memory in Dyt1 DeltaGAG knock-in mice. Neurosci Res 2009; 65: 228–235.
- 38 Balas M, Peretz C, Badarny S, Scott RB, Giladi N. Neuropsychological profile of DYT1 dystonia. Mov Disord 2006; 21: 2073–2077.
- 39 Song CH, Fan X, Exeter CJ, Hess EJ, Jinnah HA. Functional analysis of dopaminergic systems in a DYT1 knock-in mouse model of dystonia. Neurobiol Dis 2012; 48: 66–78.
- 40 Dang MT, Yokoi F, Cheetham CC, et al. An anticholinergic reverses motor control and corticostriatal LTD deficits in Dyt1 ΔGAG knock-in mice. Behav Brain Res 2012; 226: 465–472.
- 41 Asanuma K, Ma Y, Okulski J, et al. Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation. Neurology 2005; 64: 347–349.
- 42 Ulug AM, Vo A, Argyelan M, et al. Cerebellothalamocortical pathway abnormalities in torsinA DYT1 knock-in mice. Proc Natl Acad Sci U S A 2011; 108: 6638–6643.
- 43 Carbon M, Kingsley PB, Su S, et al. Microstructural white matter changes in carriers of the DYT1 gene mutation. Ann Neurol 2004; 56: 283–286.
- 44 Carbon M, Ghilardi MF, Argyelan M, Dhawan V, Bressman SB, Eidelberg D. Increased cerebellar activation during sequence learning in DYT1 carriers: an equiperformance study. Brain 2008; 131(pt 1): 146–154.
- 45 Argyelan M, Carbon M, Niethammer M, et al. Cerebellothalamocortical connectivity regulates penetrance in dystonia. J Neurosci 2009; 29: 9740–9747.
- 46 Kakazu Y, Koh JY, Ho KW, Gonzalez-Alegre P, Harata NC. Synaptic vesicle recycling is enhanced by torsinA that harbors the DYT1 dystonia mutation. Synapse 2012; 66: 453–464.
- 47 Kakazu Y, Koh JY, Iwabuchi S, Gonzalez-Alegre P, Harata NC. Miniature release events of glutamate from hippocampal neurons are influenced by the dystonia-associated protein torsinA. Synapse 2012; 66: 807–822.
- 48 Yokoi F, Yang G, Li J, DeAndrade MP, Zhou T, Li Y. Earlier onset of motor deficits in mice with double mutations in Dyt1 and Sgce. J Biochem 2010; 148: 459–466.
- 49 Giles LM, Chen J, Li L, Chin LS. Dystonia-associated mutations cause premature degradation of torsinA protein and cell-type-specific mislocalization to the nuclear envelope. Hum Mol Genet 2008; 17: 2712–2722.
- 50 Gordon KL, Gonzalez-Alegre P. Consequences of the DYT1 mutation on torsinA oligomerization and degradation. Neuroscience 2008; 157: 588–595.
- 51 Dang MT, Yokoi F, Pence MA, Li Y. Motor deficits and hyperactivity in Dyt1 knockdown mice. Neurosci Res 2006; 56: 470–474.
- 52 Yokoi F, Dang MT, Mitsui S, Li J, Li Y. Motor deficits and hyperactivity in cerebral cortex-specific Dyt1 conditional knockout mice. J Biochem 2008; 143: 39–47.
- 53 Yokoi F, Dang MT, Li Y. Improved motor performance in Dyt1 ΔGAG heterozygous knock-in mice by cerebellar Purkinje-cell specific Dyt1 conditional knocking-out. Behav Brain Res 2012; 230: 389–398.
- 54 Jin XL, Guo H, Mao C, et al. Emx1-specific expression of foreign genes using “knock-in” approach. Biochem Biophys Res Commun 2000; 270: 978–982.
- 55 Dang MT, Yokoi F, Yin HH, Lovinger DM, Wang Y, Li Y. Disrupted motor learning and long-term synaptic plasticity in mice lacking NMDAR1 in the striatum. Proc Natl Acad Sci U S A 2006; 103: 15254–15259.
- 56 Yokoi F, Dang MT, Li J, Standaert DG, Li Y. Motor deficits and decreased striatal dopamine receptor 2 binding activity in the striatum-specific Dyt1 conditional knockout mice [serial online]. PLoS One 2011; 6: e24539.
- 57 Rossi J, Balthasar N, Olson D, et al. Melanocortin-4 receptors expressed by cholinergic neurons regulate energy balance and glucose homeostasis. Cell Metab 2011; 13: 195–204.
- 58 Sciamanna G, Hollis R, Ball C, et al. Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA. Neurobiol Dis 2012; 47: 416–427.
- 59 LeDoux MS, Lorden JF, Ervin JM. Cerebellectomy eliminates the motor syndrome of the genetically dystonic rat. Exp Neurol 1993; 120: 302–310.
- 60 Campbell DB, North JB, Hess EJ. Tottering mouse motor dysfunction is abolished on the Purkinje cell degeneration (pcd) mutant background. Exp Neurol 1999; 160: 268–278.
- 61 Barski JJ, Dethleffsen K, Meyer M. Cre recombinase expression in cerebellar Purkinje cells. Genesis 2000; 28(3-4): 93–98.
- 62 Zhang L, Yokoi F, Jin YH, et al. Altered Dendritic Morphology of Purkinje cells in Dyt1 DeltaGAG knock-in and Purkinje cell-specific Dyt1 conditional knockout mice [serial online]. PLoS One 2011; 6: e18357.
- 63 Hoshi E, Tremblay L, Feger J, Carras PL, Strick PL. The cerebellum communicates with the basal ganglia. Nat Neurosci 2005; 8: 1491–1493.
- 64 Shashidharan P, Sandu D, Potla U, et al. Transgenic mouse model of early-onset DYT1 dystonia. Hum Mol Genet 2005; 14: 125–133.
- 65 Lange N, Hamann M, Shashidharan P, Richter A. Behavioural and pharmacological examinations in a transgenic mouse model of early-onset torsion dystonia. Pharmacol Biochem Behav 2011; 97: 647–655.
- 66 Sharma N, Baxter MG, Petravicz J, et al. Impaired motor learning in mice expressing torsinA with the DYT1 dystonia mutation. J Neurosci 2005; 25: 5351–5355.
- 67 Zhao Y, DeCuypere M, LeDoux MS. Abnormal motor function and dopamine neurotransmission in DYT1 DeltaGAG transgenic mice. Exp Neurol 2008; 210: 719–730.
- 68 Balcioglu A, Kim MO, Sharma N, Cha JH, Breakefield XO, Standaert DG. Dopamine release is impaired in a mouse model of DYT1 dystonia. J Neurochem 2007; 102: 783–788.
- 69 Hewett J, Johanson P, Sharma N, Standaert D, Balcioglu A. Function of dopamine transporter is compromised in DYT1 transgenic animal model in vivo. J Neurochem 2010; 113: 228–235.
- 70 Martella G, Tassone A, Sciamanna G, et al. Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. Brain 2009; 132(pt 9): 2336–2349.
- 71 Sciamanna G, Tassone A, Mandolesi G, et al. Cholinergic dysfunction alters synaptic integration between thalamostriatal and corticostriatal inputs in DYT1 dystonia. J Neurosci 2012; 32: 11991–12004.
- 72 Pisani A, Martella G, Tscherter A, et al. Altered responses to dopaminergic D2 receptor activation and N-type calcium currents in striatal cholinergic interneurons in a mouse model of DYT1 dystonia. Neurobiol Dis 2006; 24: 318–325.
- 73 Sciamanna G, Tassone A, Martella G, et al. Developmental profile of the aberrant dopamine D2 receptor response in striatal cholinergic interneurons in DYT1 dystonia [serial online]. PLoS One 2011; 6: e24261.
- 74 Napolitano F, Pasqualetti M, Usiello A, et al. Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. Neurobiol Dis 2010; 38: 434–445.
- 75 Sciamanna G, Bonsi P, Tassone A, et al. Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. Neurobiol Dis 2009; 34: 133–145.
- 76 Page ME, Bao L, Andre P, et al. Cell-autonomous alteration of dopaminergic transmission by wild type and mutant (DeltaE) TorsinA in transgenic mice. Neurobiol Dis 2010; 39: 318–326.
- 77 Grundmann K, Reischmann B, Vanhoutte G, et al. Overexpression of human wildtype torsinA and human DeltaGAG torsinA in a transgenic mouse model causes phenotypic abnormalities. Neurobiol Dis 2007; 27: 190–206.
- 78 Grundmann K, Glockle N, Martella G, et al. Generation of a novel rodent model for DYT1 dystonia. Neurobiol Dis 2012; 47: 61–74.
- 79 Zimprich A, Grabowski M, Asmus F, et al. Mutations in the gene encoding epsilon-sarcoglycan cause myoclonus-dystonia syndrome. Nat Genet 2001; 29: 66–69.
- 80 Asmus F, Zimprich A, Tezenas Du Montcel S, et al. Myoclonus-dystonia syndrome: epsilon-sarcoglycan mutations and phenotype. Ann Neurol 2002; 52: 489–492.
- 81 Foncke EM, Gerrits MC, van Ruissen F, et al. Distal myoclonus and late onset in a large Dutch family with myoclonus-dystonia. Neurology 2006; 67: 1677–1680.
- 82 Piras G, El Kharroubi A, Kozlov S, et al. Zac1 (Lot1), a potential tumor suppressor gene, and the gene for epsilon-sarcoglycan are maternally imprinted genes: identification by a subtractive screen of novel uniparental fibroblast lines. Mol Cell Biol 2000; 20: 3308–3315.
- 83 Yokoi F, Dang MT, Mitsui S, Li Y. Exclusive paternal expression and novel alternatively spliced variants of epsilon-sarcoglycan mRNA in mouse brain. FEBS Lett 2005; 579: 4822–4828.
- 84 Ritz K, van Schaik BD, Jakobs ME, et al. SGCE isoform characterization and expression in human brain: implications for myoclonus-dystonia pathogenesis? Eur J Hum Genet 2011; 19: 438–444.
- 85 Ettinger AJ, Feng G, Sanes JR. epsilon-Sarcoglycan, a broadly expressed homologue of the gene mutated in limb-girdle muscular dystrophy 2D. J Biol Chem 1997; 272: 32534–32538.
- 86 Ettinger AJ, Feng G, Sanes JR. epsilon-Sarcoglycan, a broadly expressed homologue of the gene mutated in limb-girdle muscular dystrophy 2D [erratum]. J Biol Chem 1998; 273: 19922.
- 87 Yokoi F, Dang MT, Li J, Li Y. Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in epsilon-sarcoglycan deficient mice. J Biochem 2006; 140: 141–146.
- 88 Lancioni A, Rotundo IL, Kobayashi YM, et al. Combined deficiency of alpha and epsilon sarcoglycan disrupts the cardiac dystrophin complex. Hum Mol Genet 2011; 20: 4644–4654.
- 89 Schwenk F, Baron U, Rajewsky K. A cre-transgenic mouse strain for the ubiquitous deletion of loxP-flanked gene segments including deletion in germ cells. Nucleic Acids Res 1995; 23: 5080–5081.
- 90 Hubsch C, Vidailhet M, Rivaud-Pechoux S, et al. Impaired saccadic adaptation in DYT11 dystonia. J Neurol Neurosurg Psychiatry 2011; 82: 1103–1106.
- 91 Prsa M, Thier P. The role of the cerebellum in saccadic adaptation as a window into neural mechanisms of motor learning. Eur J Neurosci 2011; 33: 2114–2128.
- 92 Nagano A, Arahata K. Nuclear envelope proteins and associated diseases. Curr Opin Neurol 2000; 13: 533–539.
- 93 Yokoi F, Dang MT, Zhou T, Li Y. Abnormal nuclear envelopes in the striatum and motor deficits in DYT11 myoclonus-dystonia mouse models. Hum Mol Genet 2012; 21: 916–925.
- 94 Yokoi F, Dang MT, Yang G, et al. Abnormal nuclear envelope in the cerebellar Purkinje cells and impaired motor learning in DYT11 myoclonus-dystonia mouse models. Behav Brain Res 2012; 227: 12–20.
- 95 Beukers RJ, Booij J, Weisscher N, Zijlstra F, van Amelsvoort TA, Tijssen MA. Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur J Nucl Med Mol Imaging 2009; 36: 269–274.
- 96 Zhang L, Yokoi F, Parsons DS, Standaert DG, Li Y. Alteration of striatal dopaminergic neurotransmission in a mouse model of DYT11 myoclonus-dystonia [serial online]. PLoS One 2012; 7: e33669.
- 97 Brashear A, Dobyns WB, de Carvalho Aguiar P, et al. The phenotypic spectrum of rapid-onset dystonia-parkinsonism (RDP) and mutations in the ATP1A3 gene. Brain 2007; 130(pt 3): 828–835.
- 98 Dobyns WB, Ozelius LJ, Kramer PL, et al. Rapid-onset dystonia-parkinsonism. Neurology 1993; 43: 2596–2602.
- 99 Linazasoro G, Indakoetxea B, Ruiz J, Van Blercom N, Lasa A. Possible sporadic rapid-onset dystonia-parkinsonism. Mov Disord 2002; 17: 608–609.
- 100 Pittock SJ, Joyce C, O'Keane V, et al. Rapid-onset dystonia-parkinsonism: a clinical and genetic analysis of a new kindred. Neurology 2000; 55: 991–995.
- 101 Zaremba J, Mierzewska H, Lysiak Z, Kramer P, Ozelius LJ, Brashear A. Rapid-onset dystonia-parkinsonism: a fourth family consistent with linkage to chromosome 19q13. Mov Disord 2004; 19: 1506–1510.
- 102 Brashear A, DeLeon D, Bressman SB, Thyagarajan D, Farlow MR, Dobyns WB. Rapid-onset dystonia-parkinsonism in a second family. Neurology 1997; 48: 1066–1069.
- 103 de Carvalho Aguiar P, Sweadner KJ, Penniston JT, et al. Mutations in the Na+/K+-ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron 2004; 43: 169–175.
- 104 Cannon SC. Pathomechanisms in channelopathies of skeletal muscle and brain. Annu Rev Neurosci 2006; 29: 387–415.
- 105 Moseley AE, Williams MT, Schaefer TL, et al. Deficiency in Na,K-ATPase alpha isoform genes alters spatial learning, motor activity, and anxiety in mice. J Neurosci 2007; 27: 616–626.
- 106 DeAndrade MP, Yokoi F, van Groen T, Lingrel JB, Li Y. Characterization of Atp1a3 mutant mice as a model of rapid-onset dystonia with parkinsonism. Behav Brain Res 2011; 216: 659–665.
- 107 Kirshenbaum GS, Saltzman K, Rose B, Petersen J, Vilsen B, Roder JC. Decreased neuronal Na+, K+-ATPase activity in Atp1a3 heterozygous mice increases susceptibility to depression-like endophenotypes by chronic variable stress. Genes Brain Behav 2011; 10: 542–550.
- 108Karp BI. Botulinum toxin physiology in focal hand and cranial dystonia. Toxins (Basel) 2012; 4: 1404–1414.
- 109 Yu H, Neimat JS. The treatment of movement disorders by deep brain stimulation. Neurotherapeutics 2008; 5: 26–36.
- 110 Cao S, Hewett JW, Yokoi F, et al. Chemical enhancement of torsinA function in cell and animal models of torsion dystonia. Dis Model Mech 2010; 3(5-6): 386–396.
- 111 Carroll D. Genome engineering with zinc-finger nucleases. Genetics 2011; 188: 773–782.
- 112 Yan Z, Sun X, Engelhardt JF. Progress and prospects: techniques for site-directed mutagenesis in animal models. Gene Ther 2009; 16: 581–588.
- 113 Maeder ML, Thibodeau-Beganny S, Osiak A, et al. Rapid "open-source" engineering of customized zinc-finger nucleases for highly efficient gene modification. Mol Cell 2008; 31: 294–301.
- 114 Reyon D, Kirkpatrick JR, Sander JD, et al. ZFNGenome: a comprehensive resource for locating zinc finger nuclease target sites in model organisms [serial online]. BMC Genomics 2011; 12: 83.
- 115 Tanabe LM, Martin C, Dauer WT. Genetic background modulates the phenotype of a mouse model of DYT1 dystonia [serial online]. PLoS One 2012; 7: e32245.